<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04520516</url>
  </required_header>
  <id_info>
    <org_study_id>APHP 200014</org_study_id>
    <nct_id>NCT04520516</nct_id>
  </id_info>
  <brief_title>Auricular Vagus Nerve Stimulation in Painful and Inflammatory Erosive Hand Osteoarthritis</brief_title>
  <acronym>ESTIVAL</acronym>
  <official_title>Trial of Auricular Vagus Nerve Stimulation in Painful and Inflammatory Erosive Hand Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Schwa medico (device lending)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Erosive hand osteoarthritis (EHOA) is a difficult-to-treat subtype of HOA characterized by&#xD;
      local and systemic low-grade inflammation as well as by high level of pain and of disability.&#xD;
&#xD;
      Auricular transcutaneous vagus nerve stimulation (tVNS) is a promising therapeutic strategy&#xD;
      that may reduce inflammation and pain level.&#xD;
&#xD;
      ESTIVAL is a 12 weeks randomized sham-controlled trial investigating the symptomatic efficacy&#xD;
      and safety of tVNS in patients with symptomatic and inflammatory EHOA.&#xD;
&#xD;
      tVNS will be performed using a transcutaneous electrical nerve stimulation (TENS) device&#xD;
      connected to an auricular electrode stimulating the cutaneous area of the left ear innervated&#xD;
      by the auricular ascendant branch of the vagus nerve.&#xD;
&#xD;
      The active and sham device's will display similar appearance but the sham one will not give&#xD;
      electric signal.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Symptomatic hand osteoarthritis (HOA) affects 8-16% of the general population above 50 years&#xD;
      and involves interphalangeal (IP) joints. HOA symptoms include pain, stiffness and are&#xD;
      responsible for disability and substantial burden. Erosive HOA (EHOA) (10% prevalence among&#xD;
      symptomatic HOA from the general population and 40-50% prevalence in tertiary centers) is the&#xD;
      most severe HOA phenotype characterized by inflammatory flares, more IP joint destruction,&#xD;
      pain, soft swelling joints (ie, synovitis), and more disability (similar to rheumatoid&#xD;
      arthritis (RA)) than its non-erosive counterpart.&#xD;
&#xD;
      Current symptomatic pharmacological treatments of HOA or EHOA have a poor efficacy on pain&#xD;
      (ie, paracetamol) or safety issues (ie, non-steroidal anti-inflammatory drugs (NSAIDs)) in&#xD;
      this aging population with frequent comorbidities. Systemic and joint inflammation contribute&#xD;
      to EHOA but 4 studies using TNF inhibitors, 2 using hydroxychloroquine, 1 using methotrexate&#xD;
      and 1 using a new anti-IL1α/β failed to show any efficacy on pain in HOA or in EHOA.&#xD;
      Therefore, innovative therapeutic approaches are awaited.&#xD;
&#xD;
      Stimulation of the vagus nerve (VNS), belonging to parasympathetic system, dampens&#xD;
      pro-inflammatory cytokines production by splenic macrophages, through to the binding of&#xD;
      acetylcholine neurotransmitter to α7nicotinic receptor on macrophages: this is the&#xD;
      cholinergic anti-inflammatory pathway (CAP). VN stimulation (VNS) by cervical implantable&#xD;
      device activating CAP has given promising results in refractory RA patients. Beyond its&#xD;
      anti-inflammatory effects, VNS is analgesic in chronic pain disorders (headache,&#xD;
      fibromyalgia). However, the use of such implantable device is limited by the need of cervical&#xD;
      surgery and subsequent potential side effects.&#xD;
&#xD;
      Besides implantable devices, VNS may be also performed using transcutaneous VNS (tVNS) of the&#xD;
      ascendant auricular branch of the VN that selectively innervates the cutaneous zone of cymba&#xD;
      conchae at the left ear. Auricular tVNS avoids invasive neurosurgery and its potential side&#xD;
      effects and is less expensive than implantable VNS, making it an attractive candidate for&#xD;
      neurostimulation. Auricular tVNS has given positive results in chronic migraine and is&#xD;
      currently tested in RA, Crohn's disease, widespread pain, irritable bowel syndrome and&#xD;
      musculoskeletal pain related to systemic lupus.&#xD;
&#xD;
      We hypothesize that auricular tVNS using a transcutaneous electrical nerve stimulation (TENS)&#xD;
      device could be a novel, simple and well-tolerated analgesic and anti-inflammatory treatment&#xD;
      of symptomatic (i.e., painful) and inflammatory EHOA.&#xD;
&#xD;
      ESTIVAL is a 12 weeks randomized sham-controlled trial investigating the symptomatic efficacy&#xD;
      and the safety of tVNS in patients with symptomatic and inflammatory EHOA.&#xD;
&#xD;
      tVNS will be performed using an active or sham transcutaneous electrical nerve stimulation&#xD;
      (TENS) device connected to an auricular electrode stimulating the cutaneous area of the left&#xD;
      ear innervated by the auricular ascendant branch of the vagus nerve.&#xD;
&#xD;
      Exploratory and ancillary studies will include i) changes of serum biomarkers of inflammation&#xD;
      and of cartilage degradation that will be assess at inclusion and at week 12 ii) hand MRI at&#xD;
      W0 and W12 of the most symptomatic joint at inclusion for HOAMRIS socring at W0 and W12&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 8, 2021</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain</measure>
    <time_frame>12 weeks</time_frame>
    <description>Difference D0-W12 of self-reported hand pain in the previous 48h measured on a 100 mm visual analogue scale (VAS) : &quot;How much pain in your hands did you experience during the past 48 h?&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pain, function, stiffness</measure>
    <time_frame>12 weeks</time_frame>
    <description>AUStralian CANadian Osteoarthritis Hand Index (AUSCAN) 3.1 pain, function and stiffness subscores (for each subscore: 0-100 mm scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Function</measure>
    <time_frame>12 weeks</time_frame>
    <description>Modified Functional Index for Hand OsteoArthritis (FIHOA) scale minimum 0 , and maximum 30.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>global response to treatment (on pain, function and global assessment)</measure>
    <time_frame>12 weeks</time_frame>
    <description>proportion of OMERACT-OARSI responders</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>12 weekd</time_frame>
    <description>percentage of patients below the Patient Acceptable Symptom State (PASS) of pain (VAS&lt;40/100)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>side effects</measure>
    <time_frame>4, 8 and 12 weeks</time_frame>
    <description>report of side effects during the study period</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">156</enrollment>
  <condition>Osteoarthritis</condition>
  <condition>Musculoskeletal Pain</condition>
  <condition>Erosive Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>tVNS active device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VAGUSTIM device from Schwa-Medico Length of use : 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham tVNS device</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham VAGUSTIM device from Schwa-Medico Length of use : 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Active VAGUSTIM device</intervention_name>
    <description>20min/day of stimulation at 25 Hz Frequency, 50 microsec pulse width with intensity escalation up to 15 mA or below in case of auricular discomfort</description>
    <arm_group_label>tVNS active device</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham VAGUSTIM device</intervention_name>
    <description>The sham device : no electrical signal for VNS will be delivered.</description>
    <arm_group_label>Sham tVNS device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Symptomatic HOA according to the American College of Rheumatology criteria&#xD;
&#xD;
          -  Erosive HOA according to hand radiographs performed in routine practice showing ≥1&#xD;
             erosive digital joint based on Verbruggen-Veys scoring definition&#xD;
&#xD;
          -  Hand pain level ≥ 40/100 mm on VAS at inclusion at least half of days of the 30 last&#xD;
             days&#xD;
&#xD;
          -  At least ≥1 symptomatic IP joint with clinical soft swelling or erythema at inclusion&#xD;
&#xD;
          -  reported inadequate response or adverse effects or contraindication with existing&#xD;
             medication (including acetaminophen, oral NSAIDs)&#xD;
&#xD;
          -  Informed written consent&#xD;
&#xD;
          -  Patient affiliated to a social security scheme NB: Clinical inflammation, ultrasound&#xD;
             abnormalities and radiographic erosions have not have to be present in the same joint.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Isolated thumb-base OA (i.e., rhizarthrosis)&#xD;
&#xD;
          -  Predominance of the pain in the thumb base rather than digital pain&#xD;
&#xD;
          -  Other inflammatory joint disease (e.g. gout, reactive arthritis, rheumatoid arthritis,&#xD;
             psoriatic arthritis, Lyme disease)&#xD;
&#xD;
          -  Psoriasis&#xD;
&#xD;
          -  Current skin disease of the left ear (e.g., eczema, urticarial lesion, skin infection,&#xD;
             external otitis)&#xD;
&#xD;
          -  Ear canal not adapted to apply the auricular electrode&#xD;
&#xD;
          -  Known history of cardiac rhythm disturbances, atrio-ventricular block &gt; first degree,&#xD;
             or total bundle branch block&#xD;
&#xD;
          -  Symptomatic orthostatic hypotension or repeated vasovagal syncope history&#xD;
&#xD;
          -  History of vagotomy&#xD;
&#xD;
          -  Asthma&#xD;
&#xD;
          -  Treated sleep apnea&#xD;
&#xD;
          -  Existence of a pain syndrome of the upper limbs, which would interfere with the&#xD;
             monitoring of pain&#xD;
&#xD;
          -  Fibromyalgia&#xD;
&#xD;
          -  Use of other electrically active medical devices (e.g. pacemaker, TENS for chronic&#xD;
             pain)&#xD;
&#xD;
          -  Use of oral, intramuscular or intra-articular or intravenous steroids, other&#xD;
             anti-synovial agents (e.g. slow-acting anti-rheumatic drugs such as methotrexate,&#xD;
             sulfasalazine), intra-articular hyaluronic acid to the hand joints within the last 3&#xD;
             months&#xD;
&#xD;
          -  Any new hand OA treatment in the previous 2 months, including physiotherapy and&#xD;
             provision of new hand splint.&#xD;
&#xD;
          -  Planned hand surgery in the next 3 months.&#xD;
&#xD;
          -  Use of any investigational (unlicensed) drug within 3 months prior to screening.&#xD;
&#xD;
          -  Evidence of serious uncontrolled concomitant medical condition, including&#xD;
             cardiovascular, nervous system, pulmonary, renal, hepatic, endocrine,&#xD;
             gastro-intestinal disease or epilepsy, which in the opinion of the investigator makes&#xD;
             them unsuitable for the study&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
&#xD;
          -  Patient under legal protection measure (tutorship or curatorship) and patient deprived&#xD;
             of freedom&#xD;
&#xD;
          -  Use of VNS before the study&#xD;
&#xD;
          -  Use of NSAIDs or paracetamol less than 48h before the D0 visit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jérémie SELLAM, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jérémie SELLAM, Professor</last_name>
    <phone>+ 33 1 49 28 25 20</phone>
    <email>jeremie.sellam@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alice COURTIES, MD</last_name>
    <phone>+ 33 1 49 28 25 20</phone>
    <email>alice.courties@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de Rhumatologie - Hôpital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jérémie SELLAM, Prof</last_name>
      <phone>+33 (0)1 49 28 25 20</phone>
      <email>jeremie.sellam@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Alice COURTIES, MD</last_name>
      <phone>+33 (0)1 49 28 25 20</phone>
      <email>alice.courties@aphp.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 17, 2020</study_first_submitted>
  <study_first_submitted_qc>August 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2020</study_first_posted>
  <last_update_submitted>July 31, 2021</last_update_submitted>
  <last_update_submitted_qc>July 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Musculoskeletal pain</keyword>
  <keyword>Osteoarthritis</keyword>
  <keyword>Neuromodulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Musculoskeletal Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

